Physician profile
James A Green
NPI 1285671834
$6,434.34
in general payments reported to CMS, 2019-2025
43 companies · $794 in 2025
The $794 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $113 · 2021: $1,562 · 2022: $894 · 2023: $1,164 · 2024: $1,087 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959 · Travel and Lodging: $86.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,958.83 |
| Travel and Lodging | $86.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragon 28, INC. | $1,323.22 | 2021-2022 | |
| Stryker Corporation | $1,166.63 | 2019-2025 | Augment Injectable, Infinity Adaptis, Prophecy |
| Treace Medical Concepts, INC. | $1,018.91 | 2022-2025 | |
| Integra Lifesciences Corporation | $220.06 | 2022-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Kerecis Limited | $211.70 | 2021-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Horizon Therapeutics Plc | $167.21 | 2019-2021 | |
| Abbvie INC. | $148.97 | 2022-2023 | |
| Access Pro Medical, LLC | $143.77 | 2025 | Matriderm |
| Derma Sciences, INC. | $132.41 | 2019 | |
| Ibsa Pharma INC. | $125.00 | 2024 | Licart |
| Paratek Pharmaceuticals, INC. | $124.99 | 2023 | Nuzyra |
| Smith+Nephew, INC. | $122.80 | 2020-2025 | Stravix Pl, Grafix Pl |
| Ets Wound Care LLC | $122.15 | 2023-2024 | Mirragen Advanced Wound Matrix |
| Wright Medical Technology, INC. | $117.35 | 2019 | |
| Kyowa Kirin, INC. | $116.90 | 2023-2024 | Crysvita |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $110.38 | 2024-2025 | |
| Bard Peripheral Vascular, INC. | $107.14 | 2019 | |
| Organogenesis INC. | $100.48 | 2019-2022 | |
| Acera Surgical, INC. | $97.74 | 2022-2024 | Restrata Wound Matrix |
| Trice Medical, INC. | $83.29 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.45 | 2019 | |
| Novo Nordisk INC | $53.46 | 2021-2024 | Wegovy |
| Biocomposites INC | $53.03 | 2024 | |
| Aroa Biosurgery Incorporated | $43.51 | 2022 | |
| Amgen INC. | $43.27 | 2019-2023 | Evenity, Prolia |
| Reprise Biomedical, INC. | $41.79 | 2023 | Miro3d |
| Polynovo North America LLC | $34.44 | 2024 | Novosorb Btm |
| Kowa Pharmaceuticals America, INC. | $30.86 | 2023 | Seglentis, Livalo |
| Alvogen INC | $29.41 | 2024 | Teriparatide |
| Djo, LLC | $28.66 | 2025 | Cmf |
| Globus Medical, INC. | $27.89 | 2025 | Senza |
| Seqirus USA INC | $27.74 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Averitas Pharma INC. | $23.92 | 2024 | Qutenza |
| Philips North America LLC | $23.60 | 2021 | |
| Xeris Pharmaceuticals, INC. | $21.81 | 2024 | Gvoke Hypopen |
| Abbott Laboratories | $20.04 | 2024 | Freestyle Libre |
| Trilliant Surgical LLC. | $17.79 | 2019 | |
| Lilly USA, LLC | $17.11 | 2025 | Zepbound |
| Tactile Systems Technology INC | $16.98 | 2021 | |
| Nevro Corp. | $15.87 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.55 | 2024 | Austedo Xr |
| Zimmer Biomet Holdings, INC. | $14.98 | 2021 | |
| Dexcom, INC. | $13.08 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.